Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. 2010

Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark.

Lipid rafts are cholesterol-rich plasma membrane domains that regulate signal transduction. Because our earlier work indicated that raft disruption inhibited proliferation and caused cell death, we investigated here the role of membrane cholesterol, the crucial raft constituent, in the regulation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Raft disruption was achieved in normal human keratinocytes and precancerous (HaCaT) or transformed (A431) keratinocytes by cholesterol extraction or inactivation with methyl-beta-cyclodextrin, filipin III, or 5-cholestene-5-beta-ol. Lipid raft disruption did not affect PI3K binding to its main target, the epidermal growth factor receptor, nor its ability to convert phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate but impaired Akt phosphorylation at the regulatory sites Thr(308) and Ser(473). Diminished Akt activity resulted in deactivation of mammalian target of rapamycin, activation of FoxO3a, and increased sensitivity to apoptosis stimuli. Lipid raft disruption abrogated the binding of Akt and the major Akt kinase, phosphatidylinositol-dependent kinase 1, to the membrane by pleckstrin-homology domains. Thus, the integrity of lipid rafts is required for the activity of Akt and cell survival and may serve as a potential pharmacological target in the treatment of epidermal cancers.

UI MeSH Term Description Entries
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004817 Epidermis The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071316 Forkhead Box Protein O3 A forkhead box transcription factor and transcriptional activator which triggers type 1 programmed cell death (APOPTOSIS) in the absence of APOPTOSIS INHIBITING PROTEINS, including neuronal cell death induced by OXIDATIVE STRESS. It recognizes and binds to the DNA sequence 5'-(AG)TAAA(TC)A-3' and also functions in post-transcriptional regulation of the c-MYC PROTO-ONCOGENE. FOXO3 Protein,Forkhead in Rhabdomyosarcoma-Like 1 Protein,Forkhead in Rhabdomyosarcoma Like 1 Protein,Protein, FOXO3
D000078404 Epidermal Cells Cells from the outermost, non-vascular layer (EPIDERMIS) of the skin. Epidermal Cell,Epidermic Cells,Cell, Epidermal,Cell, Epidermic,Cells, Epidermic,Epidermic Cell
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic

Related Publications

Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
February 1988, The Journal of dermatology,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
March 1993, International journal of oncology,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
October 1985, The Journal of investigative dermatology,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
January 1991, Archives of dermatological research,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
December 1985, Experimental cell research,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
January 2014, Methods in molecular biology (Clifton, N.J.),
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
September 2007, Antioxidants & redox signaling,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
June 2004, Cell cycle (Georgetown, Tex.),
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
January 2002, American journal of physiology. Endocrinology and metabolism,
Damien Calay, and Dina Vind-Kezunovic, and Aurelie Frankart, and Sylviane Lambert, and Yves Poumay, and Robert Gniadecki
January 2004, Cytokine & growth factor reviews,
Copied contents to your clipboard!